Career title: Administrative staff, Biomedical Research Center, Pham Ngoc Thach University of Medicine
Workplace: Pham Ngoc Thach University of Medicine
Profession: Master of Public Administration (MPA)
Email: nguyendangduy@pnt.edu.vn
BIOGRAPHY
My name is Nguyen Dang Duy and I am very pleased to join the fungal disease project team, Tropical Medicine Research Center for Talaromycosis, Pham Ngoc Thach University of Medicine, as a human resources specialist. In my 10 years of experience working in the Personnel Department, I am now assigned to continue to work on human resources, monitor the website and be in charge of logistics. I look forward to working with everyone to contribute to the implementation of fungal disease project, enhancing the prestige and capacity of the team.
PROFESSIONAL PROGRESS
|
Time |
Workplace |
Job Title |
|
2005-2006 |
Lemuel Shattuck Hospital, Tufts Medical Center, Boston, MA |
Clinical Instructor |
|
2009 – 2018 |
John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI |
Assistant Professor of Medicine |
|
2011 – 2017 |
Center for Tropical Medicine and Global Health, University of |
Senior Research Fellow – Group Head |
|
2018 – current |
Center for Tropical Medicine and Global Health, University of Oxford, Oxford, UK |
Honorary Senior Research Fellow |
|
2019- current |
Center for Tropical Medicine and Global Health, University of Oxford, Oxford, UK |
Associate Professor of Medicine |
|
2019- current |
Duke University School of Medicine, Durham, NC |
Associate Professor Molecular Genetics and Microbiology |
|
2021 – 2022 |
Duke Center for AIDS Research |
Associate Director of the Clinical Core |
|
2022 – current |
Duke Center for AIDS Research |
Co-Director of the Clinical Core h |
SCIENTIFIC RESEARCH PROGRESS
1. Ongoing Research projects
|
No |
Name |
Start/End year |
Level |
Role of participant |
|
01 |
Tropical Medicine Research Center for Talaromycosis in Vietnam |
4/01/2022-3/31/2027 |
Reseach grant |
PI |
|
02 |
Early Phase Clinical Unit (EPCTU) |
1/14/2022 – 1/13/2032 |
Reseach grant |
Co-I |
|
03 |
NIHR Global Health Group on HIV-Associated Fungal Infection |
2022 – 2025 |
Reseach grant |
Co-I |
|
04 |
“Engagement of Policy makers and Health Care Providers for the Adoption of the WHO Package of Care for Advanced HIV Diseases in Vietnam” |
April to Oct 2022 |
Reseach grant |
PI |
|
05 |
“Mapping the IgM and IgG serological response to talaromycosis in mice and men – Deciphering acute from reactivated infection” |
6/1/2021 – 5/31/2023 |
Reseach grant |
PI |
|
06 |
“Implications of mycoviral infection in Talaromyces marneffei: an analysis of human patient samples, RNAi, and hypermutation” |
4/1/2021 – 3/31/2023 |
Reseach grant |
PI |
|
07 |
“Short Course Liposomal Amphotericin B for Talaromycosis – a Phase II RCT” |
2022-2024 |
Reseach grant |
Co-I |
|
08 |
“Making an Early Diagnosis of Talaromycosis – an Approach to Reduce Morbidity and Mortality in Advanced HIV Disease in Southeast Asia” |
2019-2024 |
Reseach grant |
PI |
|
09 |
“Molecular Mycology and Pathogenesis Training Program” |
2019-2023 |
Reseach grant |
Mentor |
|
10 |
“Development of a point of care diagnostic for the detection of Talaromyces marneffei infection” |
2020-2022 |
Reseach grant |
Co-I |
|
11 |
“Tackling a neglected HIV-associated infection – A validation study of the IgG and IgM serological responses to talaromycosis” |
2020-2021 |
Reseach grant |
Co-I |
|
12 |
“Early detection of the invasive fungal infection talaromycosis by a novel portable point-of-care platform” |
2020-2021 |
Reseach grant |
PI |
|
13 |
Open-Label, Randomized, Pilot Study of the Efficacy and Hepatic Safety of Raltegravir-based and Efavirenz-based Regimens when Given in Combination with Tenofovir and Emtricitabine in Antiretroviral-Naïve HIV-infected Subjects Co-Infected with Hepatitis C” |
2015-2021 |
Reseach grant |
Co-I/Oxford PI |
|
14 |
“Profiling the immunological response to antifungal therapy in HIV-associated talaromycosis” |
2018-2020 |
Reseach grant |
Sub-award PI |
|
15 |
“Prevalence and impact on mortality of asymptomatic Talaromyces marneffei antigenemia in patients with advanced HIV disease in Vietnam” |
2018-2020 |
Reseach grant |
Sub-award PI |
|
16 |
“A Randomised Controlled Trial of Itraconazole vs. Amphotericin B for the Induction Therapy of Penicilliosis (IVAP)” |
2011-2017 |
Reseach grant |
PI |
|
17 |
“Impact of baseline HIV-1 drug resistance in ART-naïve patients with and without virological monitoring on cART in Ha Noi, Vietnam” |
2015-2018 |
Reseach grant |
Sub-award PI |
|
18 |
“Health economics of emerging infectious diseases in Vietnam” |
2012-2014 |
Reseach grant |
PI |
|
19 |
“A Case Control Study to Evaluate the Exposure Risk Factors of Penicillium marneffei Infection in Vietnam” |
2011-2014 |
Reseach grant |
PI |
|
20 |
“Epidemiology of HIV-Associated Penicillium marneffei Infection in Vietnam” |
2009-2011 |
Reseach grant |
Personal Fellowship |
|
21 |
Prevalence and Patterns of HIV drug resistance in patients infected with HIV-1 subtype CRF-01AE during antiretroviral rollout in Vietnam” |
2009-2011 |
Reseach grant |
PI |
|
22 |
“Clinical significance of low-abundance HIV drug-resistant mutations in patients failing antiretroviral therapy using the 454 ultra-deep pyrosequencing technology” |
2007-2009 |
Reseach grant |
Personal Fellowship |
2. Published Studies
|
No |
Name |
Year Published |
Journal |
|
1 |
Effect of mutations in the Pneumocystis carinii dihydropteroate synthase gene do not affect outcome of P. carinii pneumonia in patients with HIV-1: a prospective study |
2021 |
Lancet |
|
2 |
Susceptibility of INF-gamma or IL-12 Knock-out and SCID Mice to Infection with Two Microsporidian Species, Encephalitozoon cuniculi and E. intestinalis |
2004 |
Folia Parasitologica |
|
3 |
Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use |
2009 |
PLoS ONE |
|
4 |
AIDS-associated Cryptococcal neoformans and Penicillium marneffei coinfection: a therapeutic dilemma in resourcelimited settings |
2010 |
Clin Infec Dis |
|
5 |
AIDS-Associated Penicillium marneffei infection of the Central Nervous System |
2010 |
Clin Infect Dis |
|
6 |
Epidemiology, Seasonality and Outcome Predictors of Penicillium marneffei Infection in Ho Chi Minh City, Vietnam |
2011 |
Clin Infect Dis |
|
7 |
The fall of typhoid and the rise of non-typhoid Salmonellae, Cryptococcus neoformans and Penicillium marneffei in a changing HIV landscape: Bloodstream infection trends over fifteen years in southern Vietnam |
2012 |
Trans Roy Soc Trop Med Hyg |
|
8 |
HIV-1 Drug Resistance in Antiretroviral-Naive Individuals with HIV-Associated Tuberculosis Meningitis in Ho Chi Minh City, Vietnam |
2012 |
Antivir Ther |
|
9 |
Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam |
2012 |
AIDS Res Ther |
|
10 |
Environmental Predictors and Incubation Period of AIDS-Associated Penicillium marneffei Infection in Ho Chi Minh City, Vietnam |
2018 |
Clin Infect Dis |
|
11 |
Diagnosing Rhodococcus equi Infection in High Tuberculosis Endemic Setting, a double challenge |
2015 |
J Clin Microbiol |
|
12 |
Second-Line Antiretroviral Therapy Outcome and Predictors of Mortality at the Largest HIV Treatment Centre in southern Vietnam |
2015 |
Medicine |
|
13 |
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Correspondence |
2015 |
Neurology |
|
14 |
High prevalence of PI resistance in patients failing second-line antiretroviral therapy in Vietnam |
2016 |
J Antimicrob Chemother |
|
15 |
Prevalence and patterns of Transmitted Drug Resistance in HIV-Infected Adult Patients Initiating Antiretroviral Therapy in Hanoi, Vietnam |
2015 |
J. of Biotechnology |
|
16 |
Adjunctive Dexamethasone in HIVAssociated Cryptococcal Meningitis |
2016 |
N Engl J Med |
|
17 |
Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma |
2016 |
Mycoses |
|
18 |
Invasive non-typhoidal Salmonella infections in Asia: clinical observations, disease outcomes and dominant serovars from an infectious disease hospital in Vietnam |
2016 |
Plos Neg Trop Dis |
|
19 |
Looking for Fungi in All the Right Places: Screening for Cryptococcal Disease and Other AIDS-Related Mycoses Before Antiretroviral Treatment Initiation |
2017 |
Curr Opin HIV AIDS |
|
20 |
The Impact of HCV Therapy in a high HIV-HCV prevalence population: A modeling study on people who inject Drugs in Ho Chi Minh City, Vietnam |
2017 |
PLOS One |
|
21 |
AIDS-Related Mycoses: Current Progress in the Field and Future Priorities |
2017 |
Trends Microbio |
|
22 |
A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis |
2017 |
N Engl J Med |
|
23 |
Itraconazole or Amphotericin B for Talaromycosis |
2017 |
N Engl J Med |
|
24 |
Fungal infections in HIV/AIDS |
2017 |
Lancet Infect Dis |
|
25 |
Itraconazole and antiretroviral therapy: strategies for empiric dosing: Author Reply |
2017 |
Lancet Infect Dis |
|
26 |
Clinical features of three patients with paradoxical immune reconstitution inflammatory syndrome associated with Talaromyces marneffei infection |
2018 |
Mycol Case Reports |
|
27 |
World Health Organization Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection |
2018 |
WHO |
|
28 |
Guideline Development Group for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy. Managing Advanced HIV Disease in a Public Health Approach |
2018 |
Clin Infect Dis |
|
29 |
Diagnosis and Management of Systemic Endemic Mycoses Causing Pulmonary Disease |
2018 |
Respiration |
|
30 |
Leave No One Behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries |
2018 |
Lancet Infect Dis |
|
31 |
Detection and Characterization of Human Pegivirus 2 in Vietnam |
2018 |
Emerg Infec Dis |
|
32 |
Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei |
2018 |
Antimicrob Agent Chemother |
|
33 |
Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. |
2019 |
PLoS One |
|
34 |
Effects of cotrimoxazole prophylaxis on Talaromyces marneffei infection in HIV/AIDS patients receiving antiretroviral therapy: a retrospective cohort study. |
2019 |
Emerg Micro & Infect |
|
35 |
Complete genomes for two Talaromyces marneffei clinical isolates from northern and southern Vietnam |
2020 |
Microbiol Resour Announc |
|
36 |
Superior Performance of the Novel Mp1p Immunoassay Compared to Automated Blood Culture in the Diagnosis of Talaromycosis |
2020 |
Clin Infec Dis |
|
37 |
Occult Talaromyces marneffei Infection Unveiled by a Novel Mp1p Enzyme Immunoassay |
2020 |
Open Forum Infec Dis |
|
38 |
Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, 2011-2017 |
2020 |
HIV Med |
|
39 |
Prognosis and treatment effects in HIV-associated talaromycosis |
2021 |
Med Mycol |
|
40 |
Neurocognitive trajectories after 72 weeks of first-line anti-retroviral therapy in Vietnamese adults with HIV-HCV co-infection |
2021 |
Frontiers Neurology |
|
41 |
Global Guidelines for the Diagnosis and Management of the Endemic Mycoses |
2021 |
Lancet Infect Dis |
|
42 |
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials |
2021 |
Nature Communications |
|
43 |
Pulmonary talaromycosis – a window into the immunopathogenesis of an endemic mycosis |
2021 |
Mycopathologia |
|
44 |
The Cost-Effectiveness of Amphotericin B Deoxycholate versus Itraconazole for Induction Therapy of Talaromycosis in HIV-Infected Adults in Vietnam |
2021 |
Open For Infec Dis |
|
45 |
Talaromyces marneffei promotes M2 polarization of human macrophages by downregulating SOCS3 expression and activating TLR9 pathway |
2021 |
Virulence |
|
46 |
Population pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei |
2021 |
Antimicro Agents and Chemo |
|
47 |
Curvularia alcornii aortic pseudoaneurysm following aortic valve replacement: case report and review of the literature |
2021 |
Open For Infec Dis |
|
48 |
A Global Call for Talaromycosis to be Recognized as a Neglected Tropical Disease |
2021 |
Lancet Global Health |
|
49 |
Immunologic Change over 72 Weeks following Raltegravir vs Efavirenz-based Therapy in HIV/HCV co-infected Individuals in Vietnam |
2021 |
AIDS Res Human Retrov |
|
50 |
Endemic mycoses: geographical distribution is still a work in progress |
2022 |
Lancet Infect Dis |
|
51 |
Non-invasive testing and surrogate markers in invasive fungal diseases |
2022 |
Open For Infec Dis |
|
52 |
COVID-19 Trials: Who Participates and Who Benefits? |
2022 |
The Southern Med Assoc |